According to a Wall Street Journal report, the preferred Covid-19 shot globally is the Pfizer-BioNTech vaccine.
The United States had administered 401,819,240 doses of Covid-19 vaccines in the country as of the morning of Oct. 9 and distributed 487,277,035 doses, the U.S. Centers for Disease Control and Prevention said.
Immunology is one of the more complicated areas of the life sciences, and recent studies on the long-term efficacy of the mRNA vaccines against Covid-19 are prime examples of just how complicated it can be.
Pfizer Inc. and BioNTech SE asked U.S. regulators to authorize emergency use of their Covid-19 vaccine for children ages 5 to 11, a group for whom no shot is allowed, Pfizer said on Oct. 7.
A new study helps quantify the improved protection against Covid-19 achieved with a third booster dose of the vaccine from Pfizer Inc. and BioNTech SE in cancer patients who are undergoing chemotherapy.
The effectiveness of the Pfizer Inc./BioNTech SE vaccine in preventing infection by the coronavirus dropped to 47 percent from 88 percent six months after the second dose, according to data published on Oct. 4 that U.S. health agencies considered when deciding on the need for booster shots.
Johnson & Johnson is expected to ask the U.S. Food and Drug Administration to authorize a booster for the company’s one-shot Covid-19 vaccine this week. In other news, President Biden’s chief medical advisor Dr. Anthony Fauci told CNBC that they expect the FDA to review data on Merck and Ridgeback Biotherapeutics’ new oral antiviral against Covid-19 “as quickly as they possibly can.”
Sanofi is dropping plans for the company’s own mRNA-based Covid-19 vaccine because of the dominance achieved by BioNTech-Pfizer and Moderna in using the technology to fight the pandemic, the company said on Sept. 28.
Pfizer Inc. and BioNTech SE on Sept. 28 submitted initial trial data for their Covid-19 vaccine in 5-11 year olds and said they would make a formal request with U.S. regulators for emergency use in the coming weeks.
The U.S. Centers for Disease Control and Prevention (CDC) on Sept. 24 backed a booster shot of the Pfizer and BioNTech Covid-19 vaccine for Americans aged 65 and older, adults with underlying medical conditions and adults in high-risk working and institutional settings.
